Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANS02 in advanced EGFR-mutated NSCLC
NCT07538804Phase 2Recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ANS02 in non-small cell lung cancer (NSCLC), sponsored by Avistone Biotechnology Co., Ltd.. Started Jul 2026; status: recruiting.
02
Drugs
ANS02
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07538804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538804.